Content specific to this active ingredient… Drug Information Prescribing and patient information from leading authorities Drug Master Files Type 2 master files on file at the FDA Drug Recalls For prescription drugs containing this active ingredient Exclusivity Patent and market exclusivity data Federal Register FR search results for this API FDA Approved Labelling Information found in this drug's package inserts Research Links Chemical identification and research citations Title 21 Code of Federal Regulations FDA regulations for this API

FDA Approval Activities for this Drug… Xeloda (Capecitabine) Tablets, Hoffman-LaRoche Inc NDA 20-896/S12 3/15/03 3/26/03 3/26/03 Xeloda (Capecitabine) Tablets, Roche NDA 20-896/S10 & 11 9/7/01 11/6/01 9/12/01 11/7/01 Xeloda Indications: For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthacycline containing chemotherapy. SLR-011 added a black box warning for drug-drug interaction with warfarin. Xeloda capecitabine Tablets, 150 mg and 500 mg, Roche NDA 20-896/S6, S9 4/30/01 2/6/02 04/25/03 2/6/02 Xeloda capecitabine Tablets, 150 mg and 500 mg, Hoffman-La Roche NDA 20-896 | XELODA (Capecitabine) tablets, Hoffmann-La Roche, New or Modified Indication ^ FDA's latest approval appears at the bottom of this list. ^                                                                                      A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | News Feed for each API | DMF Index | Pharma Job Search | Pharma Company News © 2009 Betterchem.com